menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months
Read More

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both
Read More

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28; additional data to be presented in late-breaking, oral presentation at AHA on November 5
Read More

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts CAMBRIDGE, Mass. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financial results and
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be
Read More

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data
Read More

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg doses, respectively,
Read More

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR reduction data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 for the
Read More

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study CAMBRIDGE, Mass. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More
RSS FEEDS
PRINT PAGE